Leaflet QSIVA 3.75mg / 23mg modified-release capsules


Indicated for: epilepsy

Substance: phentermine + topiramate (antiepileptics)

ATC: A08AA51 (Alimentary tract and metabolism | Antiobesity preparations, excl. diet products | Centrally acting antiobesity products)

The combination of phentermine and topiramate is used for the management of obesity in patients who have not succeeded in losing weight through diet and exercise. Phentermine is an appetite suppressant, while topiramate helps reduce cravings and increase feelings of fullness.

The medication is taken orally, usually once daily, and should be used as directed by your doctor. It is important to combine the treatment with a healthy lifestyle to achieve the best results.

Side effects may include insomnia, dizziness, dry mouth, constipation, or, in rare cases, psychiatric or cardiovascular disorders.

Patients should inform their doctor about any other medications being used or pre-existing conditions, such as hypertension or kidney diseases, to ensure the safe use of this combination.

General data about QSIVA 3.75mg / 23mg

  • Substance: phentermine + topiramate
  • Date of last drug list: 01-02-2025
  • Commercial code: W70852001
  • Concentration: 3.75mg / 23mg
  • Pharmaceutical form: modified-release capsules
  • Quantity: 14
  • Product type: original
  • Prescription restrictions: P-RF - Medicines prescription that is retained in the pharmacy (not renewable).

Marketing authorisation

  • Manufacturer: CATALENT GERMANY SCHORNDORF GMBH - GERMANIA
  • Holder: VIVUS BV - TARILE DE JOS
  • Number: 15766/2025/01
  • Shelf life: 3 years

Concentrations available for phentermine + topiramate

  • 11.25mg/69mg
  • 15mg/92mg
  • 3.75mg/23mg
  • 7.5mg/46mg